Compare Dolby Laboratories, Inc. (DLB) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dolby Laboratories, Inc. vs TransMedics Group Inc — how do they compare? Dolby Laboratories, Inc. trades at $58.67 (market cap $5.47B), while TransMedics Group Inc trades at $77.54 (market cap $2.74B). The key difference: Dolby Laboratories, Inc. is the larger of the two by market cap, and Dolby Laboratories, Inc. pays a 2.46% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dolby Laboratories, Inc. for 98 Days and TransMedics Group Inc for 24 Days on average.
| DLB | TMDX | |
|---|---|---|
Market Cap | $5.47B | $2.74B |
Volume | 1,058,284 | 949,331 |
Sector | Technology | Health |
52-Week High | $70.09 | $150.42 |
52-Week Low | $48.51 | $61.99 |
Typical Hold Time | 98 Days | 24 Days |
Enterprise Value | $4.85B | $3.13B |
Dividend Yield | 2.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dolby Laboratories (DLB) trades at $58.67, up 0.55% with a bearish technical signal despite recent earnings beats. The company maintains strong profitability with 87.61% gross margins and 16.7% net income margins, though revenue has remained flat around $1.3B. Recent developments include expanded partnerships with Meta and leadership transition to new CEO Marc Whitten.
DLB offers value with analyst consensus target of $90.33 (54% upside) but faces near-term execution risks and licensing volatility. The stock trades at reasonable valuations (P/E 24.87, P/S 4.15) with solid cash flow generation, though technical indicators suggest caution amid bearish momentum signals.
TransMedics Group (TMDX) trades at $80.69, down 0.47% on the day, amid a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $605.49M in 2025 with a net income margin of 22.69%, but recent quarters have seen earnings misses. Analyst sentiment remains positive with a consensus price target of $99.75 and a 69% buy rating, though news flow includes investigations into fiduciary duties.
The outlook balances robust fundamentals against near-term headwinds. Upside potential exists from the high analyst target and strong profitability metrics like a 36.28% ROE, but risks include earnings volatility, margin pressure, and ongoing legal scrutiny. The stock's current valuation at a P/E of 20.47 offers a reasonable entry if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
